Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · West Pharmaceutical Services (WST)

West Pharmaceutical General Counsel Kimberly MacKay to leave; transition ends by Dec. 31

Neutral Impact 3 of 5 leadership Written later

West Pharmaceutical Services said Senior Vice President, General Counsel and Corporate Secretary Kimberly Banks MacKay will leave the company. The company and Ms. MacKay have agreed to a transition period ending no later than December 31, 2025, and she will continue her current duties until she departs.

Key points

  • Kimberly Banks MacKay, SVP, General Counsel and Corporate Secretary, is leaving the company.
  • Transition period to end no later than December 31, 2025, to ensure continuity of responsibilities.
  • Ms. MacKay will continue her current duties until her departure.
  • Filing does not name a successor or give financial terms of the departure.

The filing

CompanyWest Pharmaceutical Services (WST)
Form8-K, current report
Filed with the SECSep 11, 2025, 4:06 PM ET
Accession number0000105770-25-000083

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:10 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 11, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.